poisar

Stocks · News reference

Lakewood-Amedex Biotherapeutics Announces Its Nu-3 Gel Was Well-Tolerated And Data Support Clinical Dose Selection For Its Upcoming Phase 2a Trial

BenzingaJul 15, 2026, 12:09 PMBenzinga Newsdesk

"These preclinical results are highly encouraging, providing evidence that our Nu-3 gel formulation has the potential to be a safe and effective, topically delivered antimicrobial," said Kelvin Cooper, Ph.D.,

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 15, 2026, 12:09 PM
Checked
Jul 15, 2026, 12:09 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading